share_log

Esperion Therapeutics | PRE 14A: Preliminary proxy statement not related to a contested matter or merger/acquisition

SEC announcement ·  Apr 3, 2023 16:13
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more